Temozolomide News and Research

RSS
CRT, EIF create £50M Cancer Research Technology Pioneer Fund

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Celldex fourth quarter net loss increases to $12.7 million

Celldex fourth quarter net loss increases to $12.7 million

JHN to initiate new Phase I immunotherapy trial in glioblastoma

JHN to initiate new Phase I immunotherapy trial in glioblastoma

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

Merck third quarter global sales increase 8% to $12.0 billion

Merck third quarter global sales increase 8% to $12.0 billion

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

Valproic acid may increase survival for brain tumor patients

Valproic acid may increase survival for brain tumor patients

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth first half 2011 commercial revenues increase 19%

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

Research targets malignant glioma stem cells

Research targets malignant glioma stem cells

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Patient enrollment complete in cilengitide Phase III study against glioblastoma

NYU Cancer Institute scientists present new research findings at ASCO 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011